{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper CI were not estimable","groupId":"OG001","lowerLimit":"3.7","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"2.7","value":"1.7"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"5.1","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of first dose of ceritinib to the date of first documented disease progression or death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive","id":"OG000","title":"Anaplastic Large Cell Lymphoma (ALCL)"},{"description":"Patients diagnosed with IMT with a confirmed translocation involving the ALK gene","id":"OG001","title":"Inflammatory Myofibroblastic Tumor (IMT)"},{"description":"Patients with GBM with a translocation involving the ALK gene","id":"OG002","title":"Glioblastoma (GBM)"},{"description":"Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).","id":"OG003","title":"Any Other ALK-positive Tumor"}],"paramType":"MEDIAN","populationDescription":"no participants met definition of PFS","reportingStatus":"POSTED","timeFrame":"Baseline, every 8 weeks until disease progression or death from any cause, assessed for up to approximately 84 weeks","title":"Progression Free Survival (PFS) Per Investigator Assessments","type":"SECONDARY","unitOfMeasure":"weeks"}